Evidence map›Paper›PMID 36033713›Full record

ArticleACS omega2022

Metabolic Signatures of Surface-Modified Poly(lactic-

Mohammad A Al-Natour, Salah Abdelrazig, Amir M Ghaemmaghami, Cameron Alexander, Dong-Hyun Kim

Abstract read
In one paragraph

Article in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mohammad A Al-NatourMolecular Therapeutics and Formulation Division, School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, U.K.
Salah AbdelrazigCentre for Analytical Bioscience, Advanced Materials and Healthcare Technologies Division, School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, U.K.ORCID https://orcid.org/0000-0001-6231-1267
Amir M GhaemmaghamiImmunology & Immuno-bioengineering Group, School of Life Sciences, Faculty of Medicine and Health Sciences, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2RD, U.K.ORCID https://orcid.org/0000-0003-3160-8759
Cameron AlexanderMolecular Therapeutics and Formulation Division, School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, U.K.ORCID https://orcid.org/0000-0001-8337-1875
Dong-Hyun KimCentre for Analytical Bioscience, Advanced Materials and Healthcare Technologies Division, School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, U.K.ORCID https://orcid.org/0000-0002-3689-2130

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polymeric nanoparticles (NPs) are widely used in preclinical drug delivery investigations, and some formulations are now in the clinic. However, the detailed effects of many NPs at the subcellular level have not been fully investigated. In this study, we used differentiated THP-1 macrophage cells, as a model, to investigate the metabolic changes associated with the use of poly (lactic-

Identifiers

PMID36033713
PMCPMC9404530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.